MCL

In part three of the 50th Anniversary series, Mayo Clinic Laboratories looks further outside the walls of Mayo Clinic. With the belief that the latest in diagnostic testing should be available to any patient, no matter where they are located, the sales force was born.

It can be hard to know when to use a rapid at-home COVID-19 test and how to interpret the results. Dr. Binnicker reviews the pros and cons of these tests, and explains when you need to get tested by a lab.

In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.   

In this episode of “Lab Medicine Rounds,” Ann Moyer, M.D., Ph.D., guest hosts Justin Kreuter, M.D., chair of the Mayo Clinic Alix School of Medicine Social Media Committee and a faculty lecturer for Harvard Macy Institute on professional use of social media, to discuss the challenges and opportunities of being a professional on social media.

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for September include the following sub-specialties: Clinical Microbiology and Infectious Disease Pathology, Cellular Therapy, Renal Pathology, and Endocrine.

In this month’s “Hot Topic,” Elitza Theel, Ph.D., discusses the modified two-tiered testing algorithm for Lyme disease entirely based on enzyme immunoassays (EIA).

John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.

Dan O’Bryan didn’t think his dizziness and lightheadedness were anything to worry about. Nearly 100 miles away, the team at Mayo Clinic that was remotely monitoring Dan’s heart could see the truth.

The following list includes updates posted to mayocliniclabs.com during the month of September.

Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision insights on prognosis and treatment options.

Representing Mayo Clinic at the event, Dr. William Morice contributed his expertise and experience as leaders from around the world redoubled their commitment to end the COVID-19 pandemic.

This "Pathways" program provides Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for September include the following sub-specialties: Biochemical Genetics, Clinical Microbiology, Hematopathology, and Molecular Pathology.

Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.